NO333742B1 - Mikrosfaerer vesentlig fri for ethvert losningsmiddel for anvendelse som medikament ment for subkutan eller intramuskulaer injeksjonsrute. - Google Patents
Mikrosfaerer vesentlig fri for ethvert losningsmiddel for anvendelse som medikament ment for subkutan eller intramuskulaer injeksjonsrute. Download PDFInfo
- Publication number
- NO333742B1 NO333742B1 NO20025552A NO20025552A NO333742B1 NO 333742 B1 NO333742 B1 NO 333742B1 NO 20025552 A NO20025552 A NO 20025552A NO 20025552 A NO20025552 A NO 20025552A NO 333742 B1 NO333742 B1 NO 333742B1
- Authority
- NO
- Norway
- Prior art keywords
- microspheres
- coating agent
- supercritical fluid
- autoclave
- active ingredient
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 11
- 239000002904 solvent Substances 0.000 title claims description 8
- 238000010255 intramuscular injection Methods 0.000 title claims description 4
- 239000007927 intramuscular injection Substances 0.000 title claims description 4
- 238000010254 subcutaneous injection Methods 0.000 title claims description 4
- 239000007929 subcutaneous injection Substances 0.000 title claims description 4
- 239000011248 coating agent Substances 0.000 claims abstract description 59
- 239000012530 fluid Substances 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 239000004480 active ingredient Substances 0.000 claims abstract description 34
- 238000003756 stirring Methods 0.000 claims abstract description 32
- 239000004615 ingredient Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims description 15
- -1 fatty acid esters Chemical class 0.000 claims description 14
- 238000005354 coacervation Methods 0.000 claims description 13
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 13
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 12
- 229940105423 erythropoietin Drugs 0.000 claims description 12
- 102000003951 Erythropoietin Human genes 0.000 claims description 11
- 108090000394 Erythropoietin Proteins 0.000 claims description 11
- 102000018997 Growth Hormone Human genes 0.000 claims description 9
- 108010051696 Growth Hormone Proteins 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 108700012941 GNRH1 Proteins 0.000 claims description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims description 6
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 6
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 6
- 102100022831 Somatoliberin Human genes 0.000 claims description 6
- 101710142969 Somatoliberin Proteins 0.000 claims description 6
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims description 6
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 claims description 6
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims description 6
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims description 6
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 6
- 239000000122 growth hormone Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 108010064733 Angiotensins Proteins 0.000 claims description 3
- 102000015427 Angiotensins Human genes 0.000 claims description 3
- 102000013585 Bombesin Human genes 0.000 claims description 3
- 108010051479 Bombesin Proteins 0.000 claims description 3
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 3
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 3
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 3
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 claims description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 3
- 229960003272 asparaginase Drugs 0.000 claims description 3
- 229940019700 blood coagulation factors Drugs 0.000 claims description 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 3
- 229960004015 calcitonin Drugs 0.000 claims description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 108010032806 molgramostim Proteins 0.000 claims description 3
- 229960003063 molgramostim Drugs 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 108010038379 sargramostim Proteins 0.000 claims description 3
- 229960002530 sargramostim Drugs 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 3
- 229960004824 triptorelin Drugs 0.000 claims description 3
- 102100020873 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 1
- 102000055025 Adenosine deaminases Human genes 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 11
- 239000007924 injection Substances 0.000 abstract description 11
- 238000000576 coating method Methods 0.000 abstract description 9
- 239000003960 organic solvent Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 description 23
- 239000002245 particle Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000011859 microparticle Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 238000000879 optical micrograph Methods 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- HJDRXEQUFWLOGJ-UHFFFAOYSA-N 1-[2-[[2-[(2-acetamido-3-hydroxypropanoyl)amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O HJDRXEQUFWLOGJ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 229920006051 Capron® Polymers 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0006587A FR2809309B1 (fr) | 2000-05-23 | 2000-05-23 | Microspheres a liberation prolongee pour administration injectable |
| PCT/FR2001/001575 WO2001089481A1 (fr) | 2000-05-23 | 2001-05-22 | Microspheres a liberation prolongee pour administration injectable et procede de preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20025552D0 NO20025552D0 (no) | 2002-11-19 |
| NO20025552L NO20025552L (no) | 2003-01-20 |
| NO333742B1 true NO333742B1 (no) | 2013-09-02 |
Family
ID=8850528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025552A NO333742B1 (no) | 2000-05-23 | 2002-11-19 | Mikrosfaerer vesentlig fri for ethvert losningsmiddel for anvendelse som medikament ment for subkutan eller intramuskulaer injeksjonsrute. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040043076A1 (xx) |
| EP (1) | EP1303259B1 (xx) |
| JP (1) | JP2003534267A (xx) |
| KR (1) | KR100787669B1 (xx) |
| CN (1) | CN1438877A (xx) |
| AR (1) | AR029667A1 (xx) |
| AU (2) | AU2001263996B2 (xx) |
| BR (1) | BR0111054A (xx) |
| CA (1) | CA2410219A1 (xx) |
| ES (1) | ES2413406T3 (xx) |
| FR (1) | FR2809309B1 (xx) |
| HU (1) | HU228702B1 (xx) |
| IL (2) | IL153046A0 (xx) |
| MX (1) | MXPA02011560A (xx) |
| NO (1) | NO333742B1 (xx) |
| TW (1) | TWI264310B (xx) |
| WO (1) | WO2001089481A1 (xx) |
| ZA (1) | ZA200209553B (xx) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| EP1197513B1 (en) | 2000-10-10 | 2005-03-30 | Kao Corporation | Process for preparing composite particles |
| US7374782B2 (en) | 2000-10-27 | 2008-05-20 | Baxter International Inc. | Production of microspheres |
| WO2003015750A1 (en) * | 2001-08-16 | 2003-02-27 | Baxter International, Inc. | Propellant-based microparticle formulations |
| US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| GB0205868D0 (en) * | 2002-03-13 | 2002-04-24 | Univ Nottingham | Polymer composite with internally distributed deposition matter |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| US20070092452A1 (en) * | 2003-07-18 | 2007-04-26 | Julia Rashba-Step | Methods for fabrication, uses, compositions of inhalable spherical particles |
| KR101137785B1 (ko) * | 2003-07-18 | 2012-04-25 | 백스터 인터내셔널 인코포레이티드 | 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물 |
| WO2005009375A2 (en) * | 2003-07-22 | 2005-02-03 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| KR100603974B1 (ko) * | 2003-12-05 | 2006-07-25 | 김갑식 | 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법 |
| FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
| DK1765294T3 (da) * | 2004-05-12 | 2008-11-10 | Baxter Int | Nukleinsyremikrokugler samt deres fremstilling og afgivelse |
| US7884085B2 (en) * | 2004-05-12 | 2011-02-08 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| EP1753404A1 (en) | 2004-05-12 | 2007-02-21 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| US7390097B2 (en) * | 2004-08-23 | 2008-06-24 | 3M Innovative Properties Company | Multiple channel illumination system |
| FR2874836B1 (fr) * | 2004-09-09 | 2007-04-27 | Pierre Fabre Medicament Sa | Procede d'enrobage de poudres |
| WO2006057374A1 (ja) * | 2004-11-29 | 2006-06-01 | Japan Science And Technology Agency | 複合微粒子の製造方法 |
| MX2007013356A (es) * | 2005-04-27 | 2008-03-26 | Baxter Int | Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas. |
| WO2007011989A2 (en) * | 2005-07-15 | 2007-01-25 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| US8475845B2 (en) * | 2005-07-15 | 2013-07-02 | Map Pharmaceuticals, Inc. | Method of particle formation |
| US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
| JP5118139B2 (ja) * | 2006-08-04 | 2013-01-16 | バクスター・インターナショナル・インコーポレイテッド | 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物 |
| EP2068845A2 (en) * | 2006-10-06 | 2009-06-17 | Baxter International Inc. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
| MX2009011218A (es) * | 2007-04-17 | 2010-02-11 | Baxter Int | Microparticulas de acido nucleico para administracion pulmonar. |
| US8968786B2 (en) | 2007-06-22 | 2015-03-03 | Board Of Regents, The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| GB0812742D0 (en) * | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| US8323615B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
| US20100047292A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing microparticles and compositions produced thereby |
| US8367427B2 (en) * | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| WO2010056657A2 (en) * | 2008-11-16 | 2010-05-20 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
| US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| EP2353588B1 (en) * | 2010-01-21 | 2015-04-15 | Agricultural Technology Research Institute | A sustained release preparation of factor IX |
| KR101156094B1 (ko) * | 2010-02-22 | 2012-06-20 | 경상대학교산학협력단 | 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너 |
| CA2855749C (en) | 2011-11-18 | 2020-05-26 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| CN102552169B (zh) * | 2012-02-17 | 2015-07-29 | 深圳市健元医药科技有限公司 | 一种醋酸阿肽地尔缓释微球制剂及其制备方法 |
| KR101421343B1 (ko) * | 2012-08-21 | 2014-07-18 | 경상대학교산학협력단 | 폴리(4-하이드록시부티레이트)-ｂ-모노메톡시(폴리에틸렌글리콜) 공중합체 나노입자, 이의 제조방법 및 이를 유효성분으로 함유하는 뇌질환 치료용 약학적 조성물 |
| WO2014051251A1 (en) * | 2012-09-28 | 2014-04-03 | Industrial Cooperation Foundation Chonbuk National University | Pvax copolymer and pvax microparticles comprising the same |
| CN102921011B (zh) * | 2012-11-09 | 2014-10-15 | 东华大学 | 一种仿血细胞形貌温敏聚合物微球及其制备方法 |
| GB201317756D0 (en) * | 2013-10-08 | 2013-11-20 | Critical Pharmaceuticals Ltd | New process |
| CA2935311C (en) * | 2013-12-31 | 2018-11-27 | Pb&B Sa | Controlled release fatty acid compositions for use in body reconstruction and body-shaping |
| CN104474533A (zh) * | 2014-11-24 | 2015-04-01 | 华南理工大学 | 一种可用于创面修复的复合微球的制备方法 |
| US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| CN108042793B (zh) * | 2017-11-13 | 2020-07-07 | 中国人民解放军第四军医大学 | 包埋gdnf的多核-单壳微球缓释系统的制备方法 |
| US20210308258A1 (en) * | 2018-08-20 | 2021-10-07 | Institute Of Process Engineering, Chinese Academy Of Sciences | Microcapsule-based vaccine |
| CN110585055B (zh) * | 2019-08-26 | 2023-06-13 | 武汉贝缇安卡医疗健康投资有限公司 | AcSDKP在增加成纤维细胞分泌Ⅲ型胶原蛋白含量的应用 |
| CN114209887B (zh) * | 2021-08-24 | 2023-03-03 | 杭州协合医疗用品有限公司 | 一种含可控降解聚酯微球的注射用凝胶 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3777721D1 (de) * | 1986-08-11 | 1992-04-30 | American Cyanamid Co | Zusammensetzungen zur parenteralen verabreichung und deren verwendung. |
| EP0706821A1 (en) * | 1994-10-06 | 1996-04-17 | Centre De Microencapsulation | Method of coating particles |
| ATE201983T1 (de) * | 1995-03-10 | 2001-06-15 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| FR2753639B1 (fr) * | 1996-09-25 | 1998-12-11 | Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede | |
| US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
| WO1998031346A1 (en) * | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
| DK1107743T3 (da) * | 1998-08-25 | 2007-10-22 | Advanced Inhalation Res Inc | Stabile, spraytörrede proteinformuleringer |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2797398B1 (fr) * | 1999-08-11 | 2002-10-18 | Mainelab | Microparticules pour administration pulmonaire |
| EP1242112A4 (en) * | 1999-12-21 | 2005-02-09 | Rxkinetix Inc | PRODUCTS CONTAINING MEDICINANT SUBSTANCE PARTICLES AND PROCESS FOR PREPARING THE SAME |
| CA2397404C (en) * | 2000-01-14 | 2008-12-02 | Brown University Research Foundation | Micronized freeze-dried particles |
| DK1280520T4 (en) * | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
-
2000
- 2000-05-23 FR FR0006587A patent/FR2809309B1/fr not_active Expired - Lifetime
-
2001
- 2001-05-22 WO PCT/FR2001/001575 patent/WO2001089481A1/fr active IP Right Grant
- 2001-05-22 EP EP01938300A patent/EP1303259B1/fr not_active Expired - Lifetime
- 2001-05-22 AU AU2001263996A patent/AU2001263996B2/en not_active Ceased
- 2001-05-22 IL IL15304601A patent/IL153046A0/xx unknown
- 2001-05-22 CN CN01809902A patent/CN1438877A/zh active Pending
- 2001-05-22 MX MXPA02011560A patent/MXPA02011560A/es not_active Application Discontinuation
- 2001-05-22 BR BR0111054-3A patent/BR0111054A/pt not_active Application Discontinuation
- 2001-05-22 HU HU0302012A patent/HU228702B1/hu not_active IP Right Cessation
- 2001-05-22 KR KR1020027015881A patent/KR100787669B1/ko not_active IP Right Cessation
- 2001-05-22 ES ES01938300T patent/ES2413406T3/es not_active Expired - Lifetime
- 2001-05-22 CA CA002410219A patent/CA2410219A1/fr not_active Abandoned
- 2001-05-22 AU AU6399601A patent/AU6399601A/xx active Pending
- 2001-05-22 US US10/296,314 patent/US20040043076A1/en not_active Abandoned
- 2001-05-22 JP JP2001585726A patent/JP2003534267A/ja active Pending
- 2001-05-23 AR ARP010102466A patent/AR029667A1/es not_active Application Discontinuation
- 2001-07-18 TW TW090112316A patent/TWI264310B/zh not_active IP Right Cessation
-
2002
- 2002-11-19 NO NO20025552A patent/NO333742B1/no not_active IP Right Cessation
- 2002-11-24 IL IL153046A patent/IL153046A/en active IP Right Grant
- 2002-11-25 ZA ZA200209553A patent/ZA200209553B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2809309A1 (fr) | 2001-11-30 |
| JP2003534267A (ja) | 2003-11-18 |
| TWI264310B (en) | 2006-10-21 |
| ES2413406T3 (es) | 2013-07-16 |
| CA2410219A1 (fr) | 2001-11-29 |
| AR029667A1 (es) | 2003-07-10 |
| MXPA02011560A (es) | 2004-09-10 |
| ZA200209553B (en) | 2003-08-26 |
| AU2001263996B2 (en) | 2006-01-19 |
| US20040043076A1 (en) | 2004-03-04 |
| HUP0302012A3 (en) | 2005-11-28 |
| HU228702B1 (en) | 2013-05-28 |
| KR100787669B1 (ko) | 2007-12-21 |
| EP1303259A1 (fr) | 2003-04-23 |
| NO20025552D0 (no) | 2002-11-19 |
| IL153046A (en) | 2013-12-31 |
| KR20030011858A (ko) | 2003-02-11 |
| WO2001089481A1 (fr) | 2001-11-29 |
| AU6399601A (en) | 2001-12-03 |
| EP1303259B1 (fr) | 2013-03-20 |
| FR2809309B1 (fr) | 2004-06-11 |
| IL153046A0 (en) | 2003-06-24 |
| NO20025552L (no) | 2003-01-20 |
| CN1438877A (zh) | 2003-08-27 |
| BR0111054A (pt) | 2003-04-15 |
| HUP0302012A2 (hu) | 2003-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333742B1 (no) | Mikrosfaerer vesentlig fri for ethvert losningsmiddel for anvendelse som medikament ment for subkutan eller intramuskulaer injeksjonsrute. | |
| US6967028B2 (en) | Prolonged release microspheres for injectable administration | |
| EP1033973B1 (en) | Encapsulation method | |
| Ansary et al. | Biodegradable poly (D, L-lactic-co-glycolic acid)-based micro/nanoparticles for sustained release of protein drugs-A review | |
| US6692770B2 (en) | Starch microparticles | |
| US6080429A (en) | Method for drying microspheres | |
| CA2172508C (en) | Method for preparing microspheres comprising a fluidized bed drying step | |
| AU2001294458B2 (en) | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight | |
| US20090104274A1 (en) | Process of making microspheres | |
| JP2004510730A (ja) | 非経口的投与可能な制御放出微粒子調製物 | |
| AU2001294458A1 (en) | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight | |
| Ogawa | Injectable microcapsules prepared with biodegradable poly (α-hydroxy) acids for prolonged release of drugs | |
| US7105181B2 (en) | Microparticles | |
| JP2004501188A (ja) | インスリンの放出制御製剤及びその方法 | |
| US20100180464A1 (en) | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture | |
| WO2002058671A1 (en) | Burst free pharmaceutical microparticules | |
| EP1333815A1 (en) | Process for producing microparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |